TP
MNTA

Traxis Partners’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Traxis Partners’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-71,628
Closed -$1.08M – 40
2013
Q2 		$1.08M Buy
+71,628
New +$945K 0.83% 56

Other funds holding MNTA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Traxis Partners's MNTA Position: Q3 2013 in Review

Traxis Partners sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2013, closing a stake of 71,628 shares — an estimated $1.08M sold.

Traxis Partners first reported a position in MNTA in Q2 2013 and held it in 1 quarter. The position peaked at $1.08M in Q2 2013. 126 funds tracked by Wall St. Rank hold MNTA as of Q3 2013.

  • Traxis Partners reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Traxis Partners sold 71,628 Momenta Pharmaceuticals, Inc. shares in Q3 2013, an estimated $1.08M.
  • Traxis Partners first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Traxis Partners's Momenta Pharmaceuticals, Inc. position peaked at $1.08M in Q2 2013.
  • 126 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2013.

Based on Traxis Partners's 13F filing for Q3 2013.